Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

IMCR

Live52w low +2.4%

Annual Quarterly

Core line items from IMCR's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: Immunocore Holdings plc·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-05	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$112.53M	$106.68M	$400.02M	$295.54M	$191.84M
Operating Income	Not available	$7.28M	$-45.35M	$-25.66M	$-18.49M
Net Income	Not available	$12.97M	$-35.51M	$-5.45M	$-10.30M
EPS (Diluted)	$-0.17	$0.25	$-0.71	$-0.11	$-0.11
Total Assets	Not available	$1.07B	$1.07B	$1.10B	$1.08B
Total Liabilities	Not available	$678.42M	$686.24M	$705.94M	$693.91M
Cash & Equivalents	Not available	$452.68M	$467.71M	$498.41M	$487.93M
Free Cash Flow OCF − CapEx	Not available	$-15.56M	$-15.05M	$20.48M	$25.69M
Shares Outstanding	Not available	50.83M	50.69M	50.47M	50.37M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from IMCR's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +2.4%

Entity: Immunocore Holdings plc·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-05	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$112.53M	$106.68M	$400.02M	$295.54M	$191.84M
Operating Income	Not available	$7.28M	$-45.35M	$-25.66M	$-18.49M
Net Income	Not available	$12.97M	$-35.51M	$-5.45M	$-10.30M
EPS (Diluted)	$-0.17	$0.25	$-0.71	$-0.11	$-0.11
Total Assets	Not available	$1.07B	$1.07B	$1.10B	$1.08B
Total Liabilities	Not available	$678.42M	$686.24M	$705.94M	$693.91M
Cash & Equivalents	Not available	$452.68M	$467.71M	$498.41M	$487.93M
Free Cash Flow OCF − CapEx	Not available	$-15.56M	$-15.05M	$20.48M	$25.69M
Shares Outstanding	Not available	50.83M	50.69M	50.47M	50.37M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.